MIRA Pharmaceuticals
MIRA
25 hedge funds and large institutions have $3.35M invested in MIRA Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 6 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
77% more capital invested
Capital invested by funds: $1.89M → $3.35M (+$1.45M)
2.02% less ownership
Funds ownership: 7.32% → 5.29% (-2%)
14% less funds holding
Funds holding: 29 → 25 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$671K |
| 2 |
Mirae Asset Global ETFs Holdings
Causeway Bay,
Hong Kong
|
+$460K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$200K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$35.2K |
| 5 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
+$29.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$63.5K |
| 2 |
JWCA
J.W. Cole Advisors
Tampa,
Florida
|
-$61.9K |
| 3 |
Two Sigma Investments
New York
|
-$27.4K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$22.1K |
| 5 |
VF
Virtu Financial
New York
|
-$17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Renaissance Technologies
New York
| – | -$63.5K | -46,700 | Closed |
|
|
JWCA
27
J.W. Cole Advisors
Tampa,
Florida
| – | -$61.9K | -45,501 | Closed |
|
|
VF
28
Virtu Financial
New York
| – | -$17K | -12,196 | Closed |
|
29
Citigroup
New York
| – | -$5.2K | -3,820 | Closed |
|
|
EWA
30
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$496 | -365 | Closed |
|
31
Fidelity Investments
Boston,
Massachusetts
| – | -$156 | -115 | Closed |
|
MIRA Hedge Fund Activity: Q4 2025 in Review
25 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in MIRA Pharmaceuticals (MIRA) for Q4 2025, worth a combined $3.35M — up 77% from $1.89M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of MIRA and 2 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $671K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $63.5K sold.
- 25 institutional investors held MIRA Pharmaceuticals (MIRA) as of Q4 2025, down from 29 in Q3 2025.
- Funds reported $3.35M of MIRA Pharmaceuticals stock for Q4 2025, up 77% quarter-over-quarter.
- 2 funds opened new MIRA Pharmaceuticals positions in Q4 2025 and 6 closed out, a net change of -4 holders.
- The largest MIRA Pharmaceuticals buyer in Q4 2025 was Vanguard Group, an estimated $671K added.
- The largest MIRA Pharmaceuticals seller in Q4 2025 was Renaissance Technologies, an estimated $63.5K sold.
Based on aggregated 13F filings for Q4 2025.